Angle Share Discussion Threads

[w t tutte] 09/1/2024 12:19

I love Banshee, he is so hard working and does make me giggle. I can just imagine him sitting there, with his tin foil hat on, bashing away at the keyboard.

Length of Test - If a test takes 4,6, 12, 24 hours or 5 days for that matter and the result is you will end up on a treatment that cures your cancer, or extends your life by months or reduces the side effects of your long treatment, how long the test take is utterly irrelevant. The additional information they were able to demonstrate that could be obtained from the CTC but was not available from the dead cancer fragments will do precisely that.

Competition - As to the competition there is none, at least none that is peer reviewed or validated and as we know at Angle that take years and years and years. I imagine as we speak, Banshee tin foil hat glinting from the single lightbulb in his darkened room, is stabbing at his keyboard firing off email after email to Eisai, Cancer Research Trust UK, Barts Cancer Institute, Abbot Labs, Illumina, Cambridge University, University of Tübingen, The University of Texas MD Anderson Cancer Center, Cannon Research Institute, University of Basel,University of Duesseldorf, Research Institute of Santiago, Montpellier University Et al. "You fools" he will write " You fools, why do you use that awful Parsortix system when there are so many other, better options to capture your CTCs. If you email with the secret Illuminati symbol of brotherhood I will be able to share the names of the competitors with you. You must not be taken in by the fools gold of peer reviews, validation and regulatory approval."

Shareholder - I am afraid to admit that I am indeed one of those long-term shareholders he highlights, one of those who really knows the terrible, dark and negative truth about Parsotix and Angle but still, I refuse, refuse I tell you, to action this knowledge and sell my shares. I wonder why I do that? is that I am lazy, maybe I have a form of Stockholm syndrome, or maybe it is just that I enjoy pain ? Whatever the reason we are so lucky to have Banshee, his certainty and clarity are like a beacon. He is a light in the darkness, selflessly and without ulterior motive he works desperately to save me and many like me, from ourselves. Please don't stop Banshee, I can do it. I am moving towards the light, my order is in, my finger is hovering over the sell button .... I am a failure, I tried, I really did but I just can't do it. Selfless Banshee you are not to blame, although, this time you failed to save me from myself, you can take comfort in the fact that you tried, in the end the failure was mine not yours.

[pj84] 09/1/2024 12:16

“Microfilter membrane microfluidics are a more simplistic group of size-based CTC separation techniques. Such devices comprise simply a filter with pores of defined sizes and shapes through which blood is passed either using a pressure regulator or by centrifugation. Such devices are generally quick and easy to use which are both key characteristics when considering clinical applicability.”;

“The ISET (Isolation by Size of Tumour Cells) (Rarecells Diagnostics, Paris, France) consists of a design of 8 μm cylindrical pores and allows for 12 samples to be filtered in parallel. In contrast to other membrane microfilters, the ISET has a relatively slow processing time whereby 10 mL blood is processed within 4 h and blood must be diluted 1:10 to prevent membrane clogging. Once loaded, the sample is filtered by applying a vacuum resulting in gentle aspiration of the sample [31]. As little as 1 mL of blood can be processed, which may be advantageous as blood draws can often be difficult in cancer patients and they also claim high sensitivity of the device with the ability to detect as little as one single tumour cell spiked into 1 mL blood [110]. They have also developed the associated CTC-biopsy system, a semi-automated CTC detection system to allow for easy enumeration following filtration.

One group carried out a direct comparison between the ISET and CellSearch in 60 patients with metastatic breast, prostate and lung cancers, with concordant results obtained in only 55% (11 of 20) of breast, 60% (12 of 20) of prostate and 20% (4 of 20) of lung cancer patients [31]. The CellSearch outperformed the ISET in breast cancer patients whilst the ISET outperformed the CellSearch in prostate and lung cancer patients and in total, 30% of patients (18 of 60) were found to have negative CTC counts with the CellSearch, whilst only 5% (3 of 60) of patients were negative with the ISET. The variability in concordance seen here clearly shows the limitations of EpCAM-based enrichment methods and also the underestimation of CTCs processed using the CellSearch. Another group compared CTCs from RCC patients using the CellSearch and ISET [111]. The CellSearch has only a 10–20% detection rate in RCC patients and the ISET showed detection rate of 36.1%. Other studies have shown the ISET is better than the CellSearch at detecting CTCs in patients with NSCLC, pancreatic, oesophageal and metastatic prostate cancer.

The ISET features in several clinical trials (Table 2), most notably the IMMUNO-PREDICT trial (NCT02827344) and the STALKLUNG01 trial (NCT02372448). The IMMUNO-PREDICT trial analyses PDL-1 expression on CTCs isolated from NSCLC patients, the detection of which would allow the stratification of patients for PDL-1 inhibitor therapy, negating the requirement for invasive biopsies. The STALKLUNG01 trial was designed to detect ALK gene rearrangements in CTCs, allowing patients with inoperable NSCLC to benefit from crizotinib treatment in instances when tumour biopsy is not feasible. Since approximately 30% of tumour biopsies contain insufficient material for ALK molecular characterisation, they concluded that CTC analysis could effectively be used in parallel with tumour biopsy analysis to allow a more complete identification of patients who would benefit from ALK inhibitor therapy [77]. Aside from lung cancer, the ISET also features in clinical trials for colon and rectal cancers (NCT02554448, NCT02979470), bronchial cancer (NCT03328559), malignant pleural mesothelioma (NCT01776385) and prostate cancer (NCT04702633).”;

[pj84] 09/1/2024 12:14

seagreen not sure if that was aimed at me but I am trying to show the full text not just the selective bits.

In particular leaving this part out "Size-based microfluidic devices are likely to pave the way for the next generation of CTC enrichment technologies due to their separation occurring independently of cell surface markers, which in theory allows the capture of the full heterogeneous population of CTCs from any type of cancer."

[banshee] 09/1/2024 12:13

I am not a shorter. Just someone with too much experience of the AGL hype machine. Hype is the only thing that really distinguishes AGL from its less hyperbolic competition imo. But then most of the competitors haven't just issued a revenue warning and have a yawning funding gap coming up.

Most Ctc co's seem to spend only a fraction of what AGL does in fact, but then I expect their CEO's earn a lot less.

[seagreen] 09/1/2024 12:06

Usual scum ADVFN short sellers trying to persuade everyone they are wrong to hold
So predictable ...LOL

[pj84] 09/1/2024 12:03

Volume of shares traded since the announcement now 100m so will be interesting to see any major changes in holdings over 3%.

[pj84] 09/1/2024 12:00

The FULL text about Parsortix from the previous 2021 article quoted.

"Size-based microfluidic devices are likely to pave the way for the next generation of CTC enrichment technologies due to their separation occurring independently of cell surface markers, which in theory allows the capture of the full heterogeneous population of CTCs from any type of cancer. These devices are based on the knowledge that CTCs (~8–30 μm) are generally larger than leukocytes (~12–15 µm) and are less deformable than other blood components. Since there is some degree of crossover between CTC and leukocyte size, it is crucial that size-based microfluidic devices are optimised in order to maximise CTC recovery rates whilst minimising inevitable leukocyte contamination rates.

The Parsortix (Angle) device has been developed with a chip containing a stepped/gradiated separation structure that gradually decreases with size, with final gap sizes ranging from 4.5 μm to 10 μm. The most common GEN3D6.5 Cell Separation Cassette has a “critical gap” size of 6.5 µm which acts to capture larger CTCs and allows other smaller, more deformable blood components to pass through [113]. The device is fairly slow at processing, taking ~4 h for 7.5 mL blood and is only semi-automated, requiring significant user input. Following cell capture, a reverse pressure is then applied to harvest the CTCs. The device is able to capture CTC clusters and there is the option for on-chip staining, however on chip imaging is difficult. Using the 6.5 µm gap size cassette, an average capture rate of 62.4% was achieved across breast- and NSCLC-derived cell lines, however purity decreases as the cassette “critical gap” size decreases [35]. The system is well suited to enrich CTCs from clinical samples (although harvested cells are not pure CTCs), taking advantage of the different physical properties (i.e., size and deformability) of the target rare cells compared to other blood components such as RBCs and WBCs.

The Parsortix is used in several clinical trials (Table 2) including those for NSCLC (NCT03771404), breast (NCT03427450), prostate (NCT04021394) and ovarian cancers (NCT02781272, NCT02785731), however no results have been published to date."

[seagreen] 09/1/2024 11:54

Or you can ignore the shorter and listen to the analysts who know the company inside out.

[banshee] 09/1/2024 11:46

Here is just one early quoted example from the paper I cited Outsize there are many more in it if you can bothered to look and it's just one paper, there are other co's and papers more coming through all time time.





" ISET technology allows the isolation of CTCs without any specific epithelial surface markers antibodies
Application for all solid tumors
High sensibility: Detection threshold of one CTC per 10 ml of blood
Isolation of CTCs and cfDNA simultaneously from the same sample
Specific ISET buffers for live and fixed cells application to preserve structural cells integrity
Compatibility with downstream processing from cytology analysis to DNA gene mutation detection
ISET® Device is CE IVD
Large scientific literature backup

DYOR

[lawson27] 09/1/2024 11:44

Surely a take-over target, i'm in for the ride, GLA

[havinthelasttoast] 09/1/2024 11:34

Don’t be fooled. Pump and dump

[bloomberg2] 09/1/2024 11:33

https://youtu.be/T84dax2MDPg?feature=shared

[outsizeclothes.com] 09/1/2024 11:27

Banshee - re:- the large amount of competition.
Can you please answer my question from last week ?
As someone who spouts about the large amount of competition - give me an answer !
Which Companies can now, commercially, extract CTCs that are unmarked, living, undamaged and viable for analysis for DNA / protein signatures ?

JUST LIST THEM BY NAME.

( & don't point to some research paper that lists technology that's not even developed yet as competition )

[banshee] 09/1/2024 11:24

As an alternatively to watching the company video you could email or even speak to some of the real world end users who will give a different picture, if reading the objective scientific papers is too much like hard work.

The reality is well known to long term holders here (or should be), but for obvious reasons they prefer to ignore it, just as the company prefers to discreetly not reference it

All Imo DYOR.

[bloomberg2] 09/1/2024 11:24

Has to be RNS first !!

[stevehuges] 09/1/2024 11:22

Over on lse site someone saying 2 commercial deals will be announced on mornings of the presentation. Hay don't shoot messenger

[sicilian_kan] 09/1/2024 11:14

Thanks boris.

On the subject of what is required to run a sample through Parsortix, this video from Angle is worth watching.

[boris cobaka] 09/1/2024 11:02

Thanks for clarifying SK

[seagreen] 09/1/2024 11:00

(Plus the king and queen of the ENET ramp who sold early and lost out)

[sawney] 09/1/2024 10:59

Your altruism knows no bounds....:-)

[seagreen] 09/1/2024 10:59

classic 33% pull back before hopefully starting the next leg up...best to read the analysts views not people who are talking their own short book who have consistantly posted negative views (circa 30 posts including weekend) since the spike and not posted on any other thread for a while. imho.

[arab3] 09/1/2024 10:50

What other shares do you hold banshee ?

[banshee] 09/1/2024 10:47

The importance of how long parsortix takes to process a blood sample (it can only do one at a time) is a critical reality check to dreams of world domination, as is the amount of manual intervention required to process a sample and the large amount of competition.

AGL always used to quote a realistic real world 1-2 samples a day, but appreciative of the the fact that this would have shareholders running for the hills imo, they now seem present a different claim on their website. You can run blood through the system as fast as you like but accuracy and ctc capture will fall of a cliff as ctcs are forced through the traps designed to catch them, that is what allows them to make these disingenuous claims imo, their end customers are experienced scientists well aware of the reality.

AGL have never released an RNS saying Parsortix has speeded up its processing, because this has not happend, had it done so they would have been RNS'ing right left and centre.

You can find an objective assessment in this, peer reviewed, non-hyping scientific paper reviewing the various different techs available and their pro's and cons. I urge all those swallowing the pre fund raising hype to read it. Do not take your info from the company website.



"The Parsortix (Angle) device has been developed with a chip containing a stepped/gradiated separation structure that gradually decreases with size, with final gap sizes ranging from 4.5 μm to 10 μm. The most common GEN3D6.5 Cell Separation Cassette has a “critical gapâ€� size of 6.5 µm which acts to capture larger CTCs and allows other smaller, more deformable blood components to pass through [113]. The device is fairly slow at processing, taking ~4 h for 7.5 mL blood and is only semi-automated, requiring significant user input. Following cell capture, a reverse pressure is then applied to harvest the CTCs. The device is able to capture CTC clusters and there is the option for on-chip staining, however on chip imaging is difficult. Using the 6.5 µm gap size cassette, an average capture rate of 62.4% was achieved across breast- and NSCLC-derived cell lines, however purity decreases as the cassette “critical gapâ€� size decreases [35]. The system is well suited to enrich CTCs from clinical samples (although harvested cells are not pure CTCs), taking advantage of the different physical properties (i.e., size and deformability) of the target rare cells compared to other blood components such as RBCs and WBCs."

AGL ALWAYS raise new funds at least 6-9 months before the existing cash runs out, check their numerous previous fund raisings. This latest wildly hyping RNS is about rebasing the share price and sucking in a few more gullible institutions to fork up another 30 million or so IMO.

The reality of 11 Years of aggressive marketing hype and spin resulting in 2.3million in sales is not enough to get them anywhere, so they have to be creative.

All imo DYOR and read the objective scientifc papers . See if you still beleive the hype when yoiu have done it.

[sicilian_kan] 09/1/2024 10:42

This is factually inaccurate from the post a few above:

"- 2023 Revenue up 120%

- 2024 Revenue expected to treble (not including any new deals)"

This would take 2024 revenue to about £6m if met...however...

The trading update RNS on 9 November stated "New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year."

So clearly when Angle states "Revenue recognised for 2024 expected to treble compared to 2023" that is totally and utterly dependent upon new deals.

[g2theary] 09/1/2024 10:40

Ha so you were wrong yesterday then when I was buying more for that 36p top again ;) that's coming this afternoon Vauxhall :D